Consolidated Financial Statements

Consolidated Balance Sheets

KANEKA CORPORATION AND CONSOLIDATED SUBSIDIARIES March 31, 2019 and 2018

arch 31, 2019 and 2018			Mill	ions of yen	Thousands of U.S. dollars
Assets		2019		2018	2019
Current assets:					
Cash and cash equivalents	¥	39,970	¥	47,414	\$ 360,123
Notes and accounts receivable - trade		147,993		142,195	1,333,391
Inventories		112,434		104,215	1,013,010
Short-term loans receivable from unconsolidated subsidiaries and affiliates		1,722		1,735	15,515
Other current assets		13,365		11,684	120,415
Allowance for doubtful accounts		(1,238)		(973)	(11,154)
Total current assets		314,246		306,270	2,831,300

Property,	plant	and	equipment:	

Land	31,355	32,545	282,503
Buildings and structures	199,621	194,565	1,798,549
Machinery, equipment and vehicles	577,115	564,428	5,199,703
Construction in progress	26,339	12,712	237,310
Other	3,697	3,728	33,309
	838,127	807,978	7,551,374
Less accumulated depreciation	586,205	570,503	5,281,602
Property, plant and equipment, net	251,922	237,475	2,269,772

Intangible assets:	13,425	9,892	120,957
Investments and other assets:			
Investment securities:			
Unconsolidated subsidiaries and affiliates	4,115	5,514	37,075
Other	57,640	63,857	519,326
Long-term loans receivable	1,100	1,229	9,911
Deferred tax assets	6,864	5,669	61,843
Other	10,537	10,145	94,938
Allowance for doubtful accounts	(261)	(270)	(2,352)
Total investments and other assets	79,995	86,144	720,741
	¥ 659,588	¥ 639,781	\$ 5,942,770

The translation of the Japanese yen amounts into U.S. dollar amounts is included solely for the convenience of readers outside Japan, using the prevailing exchange rate on March 31, 2019, which was ¥110.99 to U.S. \$1.00.

Curren	t liabilities:
Short-	term loans payable
Currer	nt portion of long-term loans payable
Currer	nt portion of bonds payable
Notes	and accounts payable:
Trade	9
Cons	truction
Othe	r
Incom	e taxes payable
Accrue	ed expenses
Other	current liabilities
Total	current liabilities
loncui	rent liabilities:
Bonds	payable
Long-t	erm loans payable
Net de	fined benefit liability
Provis	ion for directors' retirement benefits
Deferr	ed tax liabilities
Other	noncurrent liabilities
Total	noncurrent liabilities

Contingent liabilities

Net assets

Shareholders' equity: اممغم امغذ

Capital stock
Authorized—150,000,000 shares
Issued —68,000,000 shares
Capital surplus
Retained earnings
Less treasury stock, at cost—2,778,423 shares in 2019
4,456,938 shares in 2018
T (1 1 1 1 1 1 1 1 1 1

Total shareholders' equity

Accumulated other comprehensive income:

Valuation difference on available-for-sale securities

Deferred gains or losses on hedges

Foreign currency translation adjustments

Remeasurements of defined benefit plans

Total accumulated other comprehensive income

Subscription rights to shares

Non-controlling interests

Total net assets

The translation of the Japanese yen amounts into U.S. dollar amounts is included solely for the convenience of readers outside Japan, using the prevailing exchange rate on March 31, 2019, which was ¥110.99 to U.S. \$1.00.

Thousands of U.S. dollars

Millions of yen

	Ivinitoria or yerr	0.0. 001013
2019	2018	2019
¥ 63,982	¥ 50,356	\$ 576,466
3,687	9,298	33,219
10,000	—	90,098
84,797	84,914	764,006
11,545	8,373	104,018
18,682	18,971	168,321
2,865	4,481	25,813
13,764	13,514	124,011
4,590	4,975	41,357
213,912	194,882	1,927,309
_	10,000	-
45,123	45,848	406,550
34,985	37,325	315,209
266	297	2,397
2,137	1,441	19,254
2,438	3,389	21,965
84,949	98,300	765,375
33,047	33,047	297,748
32,784	32,799	295,378
272,944	264,964	2,459,176
272,011	204,004	2,400,170
(11,602)	(18,684)	(104,532)
327,173	312,126	2,947,770
19,643	24,731	176,980
(110)	(109)	(991)
(4,008)	(3,035)	(36,111)
(5,706)	(7,527)	(51,410)
9,819	14,060	88,468
0,010	1,000	00,100
432	301	3,892
23,303	20,112	209,956
360,727	346,599	3,250,086
¥ 659,588	¥ 639,781	\$ 5,942,770

Consolidated Statements of Income

KANEKA CORPORATION AND CONSOLIDATED SUBSIDIARIES Years ended March 31, 2019, 2018 and 2017

Years ended March 31, 2019, 2018 and 2017				Thousands of
			Millions of yen	U.S. dollars
	2019	2018	2017	2019
Net sales	¥ 621,044	¥ 596,143	¥ 548,222	\$ 5,595,495
Cost of sales	446,255	426,960	385,362	4,020,677
Gross profit	174,789	169,183	162,860	1,574,818
Selling, general and administrative expenses	138,747	132,294	129,695	1,250,086
Operating income	36,042	36,889	33,165	324,732
Other income (expenses):				
Interest and dividend income	1,921	1,602	1,783	17,308
Interest expenses	(2,014)	(1,692)	(1,428)	(18,146)
Gain on sales of investment securities	1,515	—	1,602	13,650
Gain on sales of property, plant and equipment	428	—	626	3,856
Loss on disposal of property, plant and equipment	(2,521)	(1,745)	(2,534)	(22,714)
Foreign exchange gains (losses), net	(334)	455	(2,270)	(3,009)
Equity in earnings of affiliates, net	30	147	118	270
Gain on negative goodwill	—	954	—	_
Litigation expenses	(1,684)	(1,088)	(963)	(15,173)
Restructuring charges	(1,851)	(1,782)	—	(16,677)
Gain on step acquisitions	444	1,430	—	4,000
Environmental expenses	—	(567)	—	—
Provision of allowance for doubtful accounts	—	(638)	—	—
Settlement received	1,052	_	—	9,478
Gain on contribution of securities to retirement benefit trust	1,608	_	—	14,488
Other, net	(2,727)	(2,880)	(1,407)	(24,569)
ncome before income taxes and non-controlling interests	31,909	31,085	28,692	287,494
ncome taxes				
Current	7,894	8,372	7,089	71,124
Deferred	40	(83)	88	360
Net income	23,975	22,796	21,515	216,010
Net income attributable to non-controlling interests	1,737	1,224	1,030	15,650
Net income attributable to owners of parent	¥ 22,238	¥ 21,572	¥ 20,485	\$ 200,360

The translation of the Japanese yen amounts into U.S. dollar amounts is included solely for the convenience of readers outside Japan, using the prevailing exchange rate on March 31, 2019, which was ¥110.99 to U.S. \$1.00.

Consolidated Statements of Comprehensive Income

KANEKA CORPORATION AND CONSOLIDATED SUBSIDIARIES

Years ended March 31, 2019, 2018 and 2017					Millio	ons of yen	Т	housands of U.S. dollars
		2019		2018		2017		2019
Net income	¥	23,975	¥	22,796	¥	21,515	\$	216,010
Other comprehensive income:								
Valuation difference on available-for-sale securities		(5,164)		2,440		5,047		(46,527)
Deferred gains or losses on hedges		(2)		(47)		(9)		(18)
Foreign currency translation adjustments		(1,178)		2,116		(4,268)		(10,613)
Remeasurements of defined benefit plans		1,800		2,154		1,248		16,218
Share of other comprehensive income of associates accounted								
for using equity method		(5)		3		(2)		(45)
Total other comprehensive income		(4,549)		6,666		2,016		(40,985)
Comprehensive income	¥	19,426	¥	29,462	¥	23,531	\$	175,025
Comprehensive income attributable to:								
Comprehensive income attributable to owners of parent	¥	17,997	¥	27,959	¥	22,597	\$	162,150
Comprehensive income attributable to non-controlling interests		1,429		1,503		934		12,875

The translation of the Japanese yen amounts into U.S. dollar amounts is included solely for the convenience of readers outside Japan, using the prevailing exchange rate on March 31, 2019, which was ¥110.99 to U.S. \$1.00.

Consolidated Statements of Changes in Net Assets

KANEKA CORPORATION AND CONSOLIDATED SUBSIDIARIES Years ended March 31, 2019, 2018 and 2017

		Millions of yen	U.S. dolla	
	2019	2018	2017	20
Shareholders' equity				
Capital stock				
Balance at beginning of year	¥ 33,047	¥ 33,047	¥ 33,047	\$ 297,7
Changes of items during the period				
Total changes of items during the period	_	_	_	
Balance at the end of current period	33,047	33,047	33,047	297,7
Capital surplus				
Balance at beginning of year	32,799	32,813	34,936	295,5
Changes of items during the period				
Change in treasury shares of parent arising from transactions				
with non-controlling interests	(15)	(14)	(2,123)	(13
Total changes of items during the period	(15)	(14)	(2,123)	(13
Balance at the end of current period	32,784	32,799	32,813	295,3
Retained earnings				
Balance at beginning of year	264,964	248,524	234,378	2,387,2
Changes of items during the period				
Dividends from surplus - ¥64.00 per share	(5,906)	(5,934)	(6,329)	(53,21
Change of scope of consolidation	_	823	_	
Net income attributable to owners of parent	22,238	21,572	20,485	200,3
Disposal of treasury stock	(0)	(21)	(10)	
Cancellation of treasury stock	(8,352)	_	_	(75,25
Total changes of items during the period	7,980	16,440	14,146	71,8
Balance at the end of current period	272,944	264,964	248,524	2,459,1
Treasury stock		- /		
Balance at beginning of year	(18,684)	(16,753)	(15,559)	(168,34
Changes of items during the period		, ,	(- / /	
Purchase of treasury stock	(1,768)	(2,619)	(1,812)	(15,92
Disposal of treasury stock	498	688	618	4,4
Cancellation of treasury stock	8,352	_	_	75,2
Total changes of items during the period	7,082	(1,931)	(1,194)	63,8
Balance at the end of current period	(11,602)	(18,684)	(16,753)	(104,53
Accumulated other comprehensive income	(11/002)	(10)00 1	(10,100)	
Valuation difference on available-for-sale securities				
Balance at beginning of year	24,731	22,338	17,451	222,8
Changes of items during the period			, -	
Net changes of items other than shareholders' equity	(5,088)	2,393	4,887	(45,84
Total changes of items during the period	(5,088)	2,393	4,887	(45,84
Balance at the end of current period	19,643	24,731	22,338	176,9
Deferred gains or losses on hedges		2 1,7 0 1		
Balance at beginning of year	(109)	(61)	(52)	(98
Changes of items during the period	(100)	(01)	(02)	,50
Net changes of items other than shareholders' equity	(1)	(48)	(9)	
Total changes of items during the period	(1)	(48)	(9)	
rotal onaligos of items during the period	(110)	(109)	(61)	(99

Thousands of

Continued on the following page.

Consolidated Statements of Cash Flows


KANEKA CORPORATION AND CONSOLIDATED SUBSIDIARIES

		Millions of yen			
	2019	2018	2017	2019	
Foreign currency translation adjustments					
Balance at beginning of year	(3,035)	(5,105)	(1,082)	(27,345)	
Changes of items during the period					
Net changes of items other than shareholders' equity	(973)	2,070	(4,023)	(8,766)	
Total changes of items during the period	(973)	2,070	(4,023)	(8,766)	
Balance at the end of current period	(4,008)	(3,035)	(5,105)	(36,111)	
Remeasurements of defined benefit plans					
Balance at beginning of year	(7,527)	(9,653)	(10,910)	(67,817)	
Changes of items during the period					
Net changes of items other than shareholders' equity	1,821	2,126	1,257	16,407	
Total changes of items during the period	1,821	2,126	1,257	16,407	
Balance at the end of current period	(5,706)	(7,527)	(9,653)	(51,410)	
Subscription rights to shares					
Balance at beginning of year	301	271	228	2,712	
Changes of items during the period					
Net changes of items other than shareholders' equity	131	30	43	1,180	
Total changes of items during the period	131	30	43	1,180	
Balance at the end of current period	432	301	271	3,892	
Non-controlling interests				-	
Balance at beginning of year	20,112	16,130	16,285	181,206	
Changes of items during the period					
Net changes of items other than shareholders' equity	3,191	3,982	(155)	28,750	
Total changes of items during the period	3,191	3,982	(155)	28,750	
Balance at the end of current period	23,303	20,112	16,130	209,956	
Total net assets					
Balance at beginning of year	346,599	321,551	308,722	3,122,795	
Changes of items during the period					
Dividends from surplus- ¥64.00 per share	(5,906)	(5,934)	(6,329)	(53,212)	
Change of scope of consolidation	_	823	_	_	
Net income attributable to owners of parent	22,238	21,572	20,485	200,360	
Purchase of treasury stock	(1,768)	(2,619)	(1,812)	(15,929)	
Disposal of treasury stock	498	667	608	4,487	
Cancellation of treasury stock	_	_	_	_	
Change in treasury shares of parent arising from transactions					
with non-controlling interests	(15)	(14)	(2,123)	(135)	
Net changes of items other than shareholders' equity	(919)	10,553	2,000	(8,280)	
Total changes of items during the period	14,128	25,048	12,829	127,291	
Balance at the end of current period	¥ 360,727	¥ 346,599	¥ 321,551	\$ 3,250,086	

The translation of the Japanese yen amounts into U.S. dollar amounts is included solely for the convenience of readers outside Japan, using the prevailing exchange rate on March 31, 2019, which was ¥110.99 to U.S. \$1.00.

			Millions of yen	Thousand U.S. do
	2019	2018	2017	2
Cash flows from operating activities				
Income before income taxes and non-controlling interests	¥ 31,909	¥ 31,085	¥ 28,692	\$ 287,
Depreciation and amortization	32,151	30,323	27,808	289,
Gain on step acquisitions	(444)	(1,430)	_	(4,0
Gain on negative goodwill	_	(954)	_	
Restructuring charges	1,851	1,782	_	16,
Settlement received	(1,052)	_	_	(9,4
Gain on contribution of securities to retirement benefit trust	(1,608)	_	_	(14,4
Increase (decrease) in net defined benefit liability	2,244	3,026	2,516	20,
Increase (decrease) in allowance for doubtful accounts	(12)	639	34	(*
Interest and dividend income	(1,921)	(1,602)	(1,783)	(17,
Interest expenses	2,014	1,692	1,428	18,
Loss (gain) on disposal of property, plant and equipment	445	531	102	4
Gain on sales of investment securities	(1,515)	_	(1,602)	(13,
Equity in earnings of affiliates, net	(30)	(147)	(118)	(2
Decrease (increase) in notes and accounts receivable-trade	(5,330)	(12,054)	(4,609)	(48,
Decrease (increase) in inventories	(9,869)	(6,176)	(4,057)	(88,
Increase (decrease) in notes and accounts payable-trade	(141)	8,568	7,304	(1,
Others	142	1,706	19	1
Subtotal	48,834	56,989	55,734	439
Interest and dividend income received	1,997	1,753	1,904	17
Interest expenses paid	(2,009)	(1,681)	(1,405)	(18,
Settlement package received	1,052		_	9
Income taxes paid	(8,761)	(7,310)	(8,113)	(78,
Net cash provided by operating activities	41,113	49,751	48,120	370
ash flows from investing activities				
Purchase of property, plant and equipment	(43,987)	(34,113)	(36,726)	(396,
Proceeds from sales of property, plant and equipment	1,706	62	1,093	15
Purchase of intangible assets	(1,810)	(1,406)	(1,474)	(16,
Purchase of investment securities	(1,607)	(1,385)	(76)	(14,
Proceeds from sales and distributions of investment securities	1,635	157	1,586	14
Purchase of shares of subsidiaries resulting in change in scope of consolidation Proceeds from purchase of shares of subsidiaries resulting in change	-	(1,464)	(102)	
in scope of consolidation	227	780	_	2
Purchase of stocks of subsidiaries and affiliates	(1,879)	_	_	(16,
Payments for transfer of business	_	(332)	_	
Payments of loans receivable	(1,221)	(934)	(315)	(11,
Collection of loans receivable	1,162	896	213	10
Others	(1,455)	(1,057)	(569)	(13,
Net cash used in investing activities	(47,229)	(38,796)	(36,370)	(425,
ash flows from financing activities				
Net increase (decrease) in short-term loans payable	13,648	6,702	(2,859)	122
Proceeds from long-term loans payable	3,811	5,628	6,251	34
Repayment of long-term loans payable	(10,881)	(9,169)	(5,986)	(98,
Proceeds from sales and leasebacks	_	232	_	
Repayments of lease obligations	(128)	(266)	(171)	(1,
Proceeds from share issuance to non-controlling shareholders	246	_	54	2
Cash dividends paid	(5,906)	(5,934)	(6,329)	(53,
Cash dividends paid to non-controlling interests	(351)	(359)	(400)	(3,
Purchase of treasury stock	(1,768)	(2,618)	(1,812)	(15,
Proceeds from sales of treasury stock	396	475	411	3
Payments from changes in ownership interests in subsidiaries				U.
that do not result in change in scope of consolidation	(22)	(82)	(2,772)	(
Net cash used in financing activities	(955)	(5,391)	(13,613)	(8,
iffect of exchange rate change on cash and cash equivalents	(373)	232	(281)	(3,
let increase (decrease) in cash and cash equivalents	(7,444)	5,796	(2,144)	(67,
Cash and cash equivalents at beginning of period	47,414	41,018	43,162	427
ncrease in cash and cash equivalents resulting from change of scope		,	.,	
of consolidation	_	600	_	
Cash and cash equivalents at end of period	¥ 39,970	¥ 47,414	¥ 41,018	\$ 360


Financial Highlights





Net income attributable to owners of parent ---- ROE (Return on equity) (Billions of Yen) (%) 7.1 7.5 25 6.9 6.8 67 21.0 6.3 20.5 22.2 21.6 20 6.0 18.0


> Net Income Attributable to Owners of Parent / ROE






> Net Assets / Shareholders' Equity Ratio






> R&D Expenses / R&D Expenses Ratio



> New Product Sales / New Product Sales Ratio







Nonfinancial Highlights

> GHG Emissions and Energy-origin CO₂ Emission Intensity Index (Baseline year: 2013)


📕 Kaneka 📕 Group companies in Japan 📕 Group companies outside Japan -CO2 emission intensity index for all parent Manufacturing Sites (right scale)



> VOC Discharge: Voluntary Plan and Performance



> Number of Female Executives




> Overseas Sales / Overseas Sales Ratio Asia North America Europe Other -Overseas sales ratio

>Waste Generated and Recycled

Amount of waste generated by Kaneka 🛛 🔳 Amount recycled by Kaneka

- Amount of waste generated by group companies in Japan
- Amount recycled by group companies in Japan
- Amount of waste generated by group companies outside Japan


Amount recycled by group companies outside Japan



>Water Consumption

📕 Kaneka 📕 Group companies in Japan 📕 Group companies outside Japan (Million m³ 25.0 22.0 21.9 21.5 21.5 21.6 20.0 15.0 9.7 10.0 7.7 7.1 6.5 6.1 5.0 0 2014 2017 2018 (Fiscal year) 2015 2016

> Employment Rate of Persons with Disabilities



Corporate Profile


Corporate Profile

Name	KANEKA CORPORATION	Facilities in	Sales Office
Offices	Tokyo Head Office 1-12-32, Akasaka, Minato-ku, Tokyo 107-6028, Japan Tel: +81-3-5574-8000 Fax: +81-3-5574-8121 Osaka Head Office 2-3-18, Nakanoshima, Kita-ku, Osaka 530-8288, Japan Tel: +81-6-6226-5050 Fax: +81-6-6226-5037	Japan Research Institutes	Nagoya (Aichi Prefecture) Manufacturing Site Takasago (Hyogo Prefecture) Osaka (Osaka Prefecture) Shiga (Shiga Prefecture) Kashima (Ibaraki Prefecture) Material Solutions New Research Engine BDP Technology Laboratories
Date of Establishment	September 1, 1949		Biotechnology Research Laboratories Regenerative Medicine and Cell Therapy Laboratories
Paid-in Capital	33,046 million yen (As of March 31, 2019)		Photovoltaic & Thin Film Device Research
Net Sales (Including consoli- dated subsidiaries)	621.043 billion yen (Fiscal year ended March 2019)		Laboratories Process Development Research Laboratories Process Technology Laboratories
Number of employees (Including consoli- dated subsidiaries)	10,571 (As of March 31, 2019)	Affiliated Companies	109 Subsidiaries (Including 42 (in Japan) and 41 (outside Japan) consolidated subsidiaries)

Investor Information (As of March 31, 2019)

Common Stock Traded	Tokyo, Nagoya	Sh
Transfer Agent	Mitsubishi UFJ Trust and Banking Corporation, Osaka Branch 3-6-3, Fushimimachi, Chuo-ku, Osaka 541-8502, Japan	
Accounting Auditor	KPMG AZSA LLC Ginsen Bingomachi Bldg., 3-6-5, Kawaramachi, Chuo-ku, Osaka 541-0048, Japan	
Authorized Capital	150,000,000 shares	
Issued Shares	68,000,000 shares	
Number of Shareholders	15,484	* S

hareholder Composition



* Share numbers are rounded down to the nearest thousand. Percentages are rounded to the nearest decimal point.

Common Stock Price Range (Tokyo Stock Exchange; Yen)

34,908,000 shares (79 shareholders)

17,007,000 shares (486 shareholders)

10,022,000 shares (14,628 shareholders)

5,365,000 shares (249 shareholders)

694,000 shares (42 shareholders)

Years ended March 31	2015	2016	2017	2018	2019
High	898	1,278	1,061	1,114	5,620
Low	558	810	643	815	3,640

* The above figures are stock prices quoted at the Tokyo Stock Exchange (First Section).

Our shares were consolidated on the basis of one new common share for five existing common shares as of October 1, 2018.

Management Management Top Message Philosophy Strategies

Global Network

EUROPE / AFRICA

Kaneka Europe Holding N.V.

- Kaneka Belgium N.V.
- Kaneka Pharma Europe N.V.
- Kaneka Eurogentec S.A.
- Kaneka Modifiers Deutschland GmbH
- Eurogentec Deutschland GmbH
- Eurogentec Proteomics GmbH



Asia Cemedine Co., Ltd.

Kaneka India Pvt. Ltd.

Showa Global (Thailand) Co., Ltd.

Cemedine (Thailand) Co., Ltd.

PT. Kaneka Foods Indonesia

Kaneka Taiwan Corporation

Taiwan Cemedine Co., Ltd.

Kaneka Korea Corporation

Showa Global Ltd.

• Cemedine Philiippines Corporation

Overseas R&D Facilities

ASIA / OCEANIA

• Kaneka Asia Co., Ltd.

- Kaneka Trading (Shanghai) Co., Ltd.
- Kaneka Eperan (Suzhou) Co., Ltd.
- HiHua Fiber Co., Ltd.
- Kaneka (Foshan) High Performance Materials Co., Ltd.
- Cemedine Shanghai Co., Ltd.
- Dalian Showa Plastic Co., Ltd.
- Kaneka (Malaysia) Sdn. Bhd.
- Kaneka Eperan Sdn. Bhd.
- Kaneka Paste Polymers Sdn. Bhd.
- Kaneka Innovative Fibers Sdn. Bhd.
- Kaneka Apical Malaysia Sdn. Bhd.
- Kaneka MS Malaysia Sdn. Bhd.
- Kaneka Singapore Co. (Pte) Ltd.
- Kaneka Pharma Vietnam Co., Ltd.
- Vina Showa Co., Ltd.
- Kaneka (Thailand) Co., Ltd.



TGA Pastry Company Pty. Ltd.

Kaneka Asia Co., Ltd. Kaneka Trading (Shanghai) Co., Ltd.

Special Feature

Business Foundation

 Eurogentec Ltd. Eurogentec France S.A.S.U. Eurogentec Nederland B.V. • AB-Biotics, S.A. Kaneka Africa Liaison Office Kaneka's European Photovoltaics Research Laboratory



Kaneka Europe Holding N.V. Kaneka Belgium N.V. Kaneka Pharma Europe N.V.

AMERICA

- Kaneka Americas Holding, Inc.
- Kaneka North America LLC
- Kaneka Pharma America LLC
- Kaneka Aerospace LLC
- Anaspec Inc.
- Cemedine North America LLC
- Eurogentec North America Inc.
- Kaneka South America Representative Ltd.
- Kaneka US Material Research Center
- Kaneka US Innovation Center



Kaneka Americas Holding, Inc. Kaneka North America LLC